Treating thalassemia major-related iron overload: the role of deferiprone
Explore this paper's citation graph
Summary
Evidence from Europe has shown that by normalizing iron stores not only are new morbidities prevented but also reversal of many complications such as cardiac failure, hypothyroidism, hypogonadism, impaired glucose tolerance, and type 2 diabetes can occur, improving survival and patients’ quality of life.
- Type
- article
- Published
- 2012-10-19
- Cited by
- 60
- References
- 109
- Access
- Open access
- OpenAlex
- https://openalex.org/W1907915660
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:18603359
Keywords
Deferiprone, Medicine, Thalassemia, Beta thalassemia, Intensive care medicine
References
- The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.
- Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit
- Predicting pituitary iron and endocrine dysfunction
- Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
- Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia
- Effect of Deferiprone on Liver Iron Overload and Fibrosis in Hepatitis C Virus-Infected Thalassemia
- Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration.
- Risk factors for death in patients with beta-thalassemia major: results of a case-control study.
- Electroretinographic and visual-evoked potential abnormalities in patients with beta-thalassemia major.
- MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients.
- Sustained normalization of cardiac function by chelation therapy in thalassaemia major.
- Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance
- Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma
- Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
- Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
- Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with β-thalassemia major
- Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.
- Follow‐up report on the 2‐year cardiac data from a deferasirox monotherapy trial
- Reversal of heart failure in thalassemia major by combined chelation therapy: a case report
- Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia.
Cited by
- Treatment of β-Thalassemia/Hemoglobin E with Antioxidant Cocktails Results in Decreased Oxidative Stress, Increased Hemoglobin Concentration, and Improvement of the Hypercoagulable State
- Distal ulnar changes in children with thalassemia and deferiprone related arthropathy
- Assessment and management of iron overload in β‐thalassaemia major patients during the 21st century: a real‐life experience from the Italian Webthal project
- Iron chelator alleviates tubulointerstitial fibrosis in diabetic nephropathy rats by inhibiting the expression of tenascinC and other correlation factors
- Ferritin: The Protein Nanocage and Iron Biomineral in Health and in Disease
- Continuing Treatment with Salvia miltiorrhiza Injection Attenuates Myocardial Fibrosis in Chronic Iron-Overloaded Mice
- Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy
- Multitargeted inhibition of hepatic fibrosis in chronic iron-overloaded mice by Salvia miltiorrhiza.
- Cost-utility of chelators in transfusion-dependent β-thalassemia major patients: a review of the pharmacoeconomic literature
- Danshen (Salvia miltiorrhiza) Injection Suppresses Kidney Injury Induced by Iron Overload in Mice
- Physiology and Pathophysiology of Iron in Hemoglobin-Associated Diseases
- Deferiprone for transfusional iron overload and its roles in developing countries
- Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients
- Comparative Study of Radiographic and Laboratory Findings Between Beta Thalassemia Major and Beta Thalassemia Intermedia Patients With and Without Treatment by Hydroxyurea
- Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
- Dual T‐type and L‐type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron‐overloaded thalassaemic mice
- Dental considerations in Thalassemic patients
- Iron overload in Beta thalassaemia major and intermedia patients.
- Desferrithiocin: A Search for Clinically Effective Iron Chelators
- Neurological Complications and Cataract in a Child With Thalassemia Major Treated With Deferiprone
Related papers
- Comment on “deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5‐year long‐term Italian multicenter randomized clinical trial”
- Advances in the Prevention and Treatment are Changing Thalassemia from a Fatal to a Chronic Disease. Experience from a Cyprus Model and its Use as a Paradigm for Future Applications
- Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients.
- Practice of iron chelation therapy for transfusion-dependent thalassemia in Southeast Asia
- Comparative Study of Deferiprone and Silymarin versus Deferiprone and Placebo as Iron Chelators in Children with Beta Thalassemia with Iron Overload
- Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
- Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia